Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2028

Conditions

Non-Small-Cell Lung Cancer

Interventions

DRUG

Vebreltinib

Vebreltinib 100mg oral BID

DRUG

Osimertinib

Osimertinib 80mg oral once daily.

Trial Locations (1)

Cancer insititue and Hospital of CHINESE ACADEMY OF MEDICAL SCIENCE, Beijing

All Listed Sponsors

collaborator

Avistone Biotechnology Co., Ltd.

INDUSTRY

lead

National Cancer Center, China

OTHER

NCT06827145 - Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC | Biotech Hunter | Biotech Hunter